SG11201906222WA - Jak1 selective inhibitors - Google Patents
Jak1 selective inhibitorsInfo
- Publication number
- SG11201906222WA SG11201906222WA SG11201906222WA SG11201906222WA SG11201906222WA SG 11201906222W A SG11201906222W A SG 11201906222WA SG 11201906222W A SG11201906222W A SG 11201906222WA SG 11201906222W A SG11201906222W A SG 11201906222WA SG 11201906222W A SG11201906222W A SG 11201906222WA
- Authority
- SG
- Singapore
- Prior art keywords
- astrazeneca
- group
- international
- molndal
- viii
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447057P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051038 WO2018134213A1 (en) | 2017-01-17 | 2018-01-16 | Jak1 selective inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906222WA true SG11201906222WA (en) | 2019-08-27 |
Family
ID=61024756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906222WA SG11201906222WA (en) | 2017-01-17 | 2018-01-16 | Jak1 selective inhibitors |
Country Status (39)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190174B1 (ar) * | 2017-01-17 | 2023-09-17 | Astrazeneca Ab | مثبطات jak1 انتقائية |
| ES2890668T3 (es) | 2017-01-26 | 2022-01-21 | Hanmi Pharm Ind Co Ltd | Compuesto de pirimidina y uso farmacéutico del mismo |
| MY209356A (en) * | 2018-07-18 | 2025-07-03 | Astrazeneca Ab | A xinafoate salt of a jak inhibiting compound |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR102669660B1 (ko) * | 2018-09-21 | 2024-05-27 | 상하이 엔노바바이오 파마슈티컬스 씨오 엘티디. | 키나아제 억제 활성을 가진 방향족 헤테로고리 화합물 |
| PH12021551985A1 (en) | 2019-02-22 | 2022-08-22 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| MX2021012749A (es) * | 2019-04-19 | 2021-11-18 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidor selectivo de la jak1 cinasa. |
| EP3991733A4 (en) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPY AGENTS |
| CN115916764B (zh) * | 2020-04-09 | 2024-09-20 | 达萨玛治疗公司 | 作为sarm1抑制剂的吲唑衍生物 |
| CN114269736B (zh) * | 2020-11-26 | 2024-02-02 | 科辉智药(深圳)新药研究中心有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| EP4297873A1 (en) * | 2021-02-26 | 2024-01-03 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| US12240836B2 (en) | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| EP4648776A1 (en) * | 2023-01-11 | 2025-11-19 | Pfizer Inc. | Compositions and methods for the treatment and/or prevention of type 1 diabetes |
| CN115974845B (zh) * | 2023-01-19 | 2024-09-20 | 奥锐特药业股份有限公司 | 奥希替尼中间体的制备方法 |
| TW202438061A (zh) * | 2023-03-16 | 2024-10-01 | 美商英塞特公司 | 用於治療氣喘之ｊａｋ１路徑抑制劑 |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200626559A (en) * | 2004-10-13 | 2006-08-01 | Wyeth Corp | Anilino-pyrimidine analogs |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
| WO2008097930A1 (en) * | 2007-02-05 | 2008-08-14 | Amira Pharmaceuticals, Inc. | Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors |
| US20100298343A1 (en) * | 2007-10-05 | 2010-11-25 | John Howard Hutchinson | 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| PE20130038A1 (es) | 2010-03-10 | 2013-01-28 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de jak1 |
| CN103209695A (zh) * | 2010-09-15 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 氮杂苯并噻唑化合物、组合物及应用方法 |
| WO2015061665A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| PT3353168T (pt) | 2015-09-25 | 2023-09-20 | Dizal Jiangsu Pharmaceutical Co Ltd | Compostos e métodos para inibir jak |
| JOP20190174B1 (ar) * | 2017-01-17 | 2023-09-17 | Astrazeneca Ab | مثبطات jak1 انتقائية |
-
2018
- 2018-01-16 JO JOP/2019/0174A patent/JOP20190174B1/ar active
- 2018-01-16 WO PCT/EP2018/051038 patent/WO2018134213A1/en not_active Ceased
- 2018-01-16 KR KR1020237032917A patent/KR102659213B1/ko active Active
- 2018-01-16 CN CN202211243959.9A patent/CN115925693B/zh active Active
- 2018-01-16 MX MX2019008435A patent/MX390625B/es unknown
- 2018-01-16 US US16/478,168 patent/US10961228B2/en active Active
- 2018-01-16 LT LTEPPCT/EP2018/051038T patent/LT3571192T/lt unknown
- 2018-01-16 CA CA3049175A patent/CA3049175A1/en active Pending
- 2018-01-16 EP EP18701296.8A patent/EP3571192B1/en active Active
- 2018-01-16 MX MX2022002976A patent/MX418519B/es unknown
- 2018-01-16 CR CR20190332A patent/CR20190332A/es unknown
- 2018-01-16 RS RS20230130A patent/RS63981B1/sr unknown
- 2018-01-16 PL PL18701296.8T patent/PL3571192T3/pl unknown
- 2018-01-16 EA EA201991700A patent/EA037067B1/ru unknown
- 2018-01-16 FI FIEP18701296.8T patent/FI3571192T3/fi active
- 2018-01-16 PH PH1/2019/501639A patent/PH12019501639B1/en unknown
- 2018-01-16 EP EP22209765.1A patent/EP4219470A1/en active Pending
- 2018-01-16 MA MA47301A patent/MA47301B1/fr unknown
- 2018-01-16 KR KR1020197023855A patent/KR102585048B1/ko active Active
- 2018-01-16 UA UAA201909176A patent/UA124246C2/uk unknown
- 2018-01-16 NZ NZ756069A patent/NZ756069A/en unknown
- 2018-01-16 SM SM20230051T patent/SMT202300051T1/it unknown
- 2018-01-16 PT PT187012968T patent/PT3571192T/pt unknown
- 2018-01-16 MY MYPI2019004083A patent/MY199735A/en unknown
- 2018-01-16 CN CN201880018044.3A patent/CN110461830B/zh active Active
- 2018-01-16 HU HUE18701296A patent/HUE061064T2/hu unknown
- 2018-01-16 PE PE2019001401A patent/PE20191108A1/es unknown
- 2018-01-16 AU AU2018209667A patent/AU2018209667B2/en active Active
- 2018-01-16 JP JP2019537377A patent/JP6986086B2/ja active Active
- 2018-01-16 SG SG11201906222WA patent/SG11201906222WA/en unknown
- 2018-01-16 HR HRP20230069TT patent/HRP20230069T1/hr unknown
- 2018-01-16 SI SI201830849T patent/SI3571192T1/sl unknown
- 2018-01-16 DK DK18701296.8T patent/DK3571192T3/da active
- 2018-01-16 ES ES18701296T patent/ES2938648T3/es active Active
- 2018-01-17 AR ARP180100104A patent/AR110753A1/es unknown
- 2018-01-17 TW TW107101685A patent/TWI753089B/zh active
-
2019
- 2019-07-04 IL IL267851A patent/IL267851B/en unknown
- 2019-07-15 CL CL2019001993A patent/CL2019001993A1/es unknown
- 2019-07-17 EC ECSENADI201951352A patent/ECSP19051352A/es unknown
- 2019-07-17 DO DO2019000184A patent/DOP2019000184A/es unknown
- 2019-07-17 NI NI201900077A patent/NI201900077A/es unknown
- 2019-07-23 CO CONC2019/0007888A patent/CO2019007888A2/es unknown
- 2019-10-18 ZA ZA2019/06875A patent/ZA201906875B/en unknown
-
2021
- 2021-03-01 US US17/188,097 patent/US11897869B2/en active Active
- 2021-11-26 JP JP2021191658A patent/JP7394820B2/ja active Active
-
2023
- 2023-10-20 JP JP2023180744A patent/JP7626819B2/ja active Active
- 2023-12-13 US US18/538,067 patent/US12473272B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201808729WA (en) | Bet protein degraders | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201809822SA (en) | Atropine-containing aqueous composition | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201810318RA (en) | Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |